NCT06622174View on ClinicalTrials.gov

Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

August 31, 2027

Conditions
Non Small Cell Lung CancerMetastatic Lung Cancer
Interventions
RADIATION

Pulse radiotherapy

Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle

Trial Locations (1)

Unknown

Centre Hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
collaborator

Varian, a Siemens Healthineers Company

INDUSTRY

lead

Houda Bahig

OTHER

NCT06622174 - Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer | Biotech Hunter | Biotech Hunter